bioRxiv Science⌕ Search

bioRxiv · 10.64898/2026.04.06.716854

Spectral Graph Features for Reference-free RNA 3D Quality Assessment

Abstract

MotivationExisting RNA 3D structure quality assessment (QA) methods rely on local geometric descriptors or statistical potentials that evaluate atomic-level contacts but are blind to global topological coherence. This creates a critical failure mode--structures that are "locally correct but globally wrong"--where well-formed local helices mask misplaced domains and incorrect overall packing. ResultsWe introduce SpecRNA-QA, a lightweight RNA QA method based on multi-scale graph-Laplacian features of inter-nucleotide contact networks. In CASP16 leave-one-out cross-validation, it achieves median per-target Spearman{rho} = 0.69 (target-clustered bootstrap 95% CI [0.64, 0.73]) versus 0.47 for an internal geometry baseline--a +0.22 gap that is significant at p = 1.2 x 10-10 (one-sided Wilcoxon signed-rank) and reflects a per-target win rate of 93%. The gain is concentrated on large, multi-domain RNAs, where global coherence is poorly captured by local descriptors. In a contextual comparison with established statistical potentials, local energy-based scores remain strongest on compact RNAs, while SpecRNA-QA yields the strongest signal we observed on targets longer than 200 nt; within the single-threaded runtime budget used here, the strongest local-energy comparator, rsRNASP, timed out on 22 of 26 large targets, and we report an explicit paired head-to-head on the four commonly scored targets in Section 4.2. A training-free heuristic variant further shows that the spectral prior carries intrinsic quality information even in the absence of labeled QA data. AvailabilitySpecRNA-QA is available as a Python package at https://github.com/yudabitrends/specrnaq. Contactybi3@gsu.edu Supplementary informationSupplementary data are available online. Key PointsO_LISpecRNA-QA uses multi-scale graph-Laplacian spectra to score global RNA fold coherence that local geometric descriptors and local statistical potentials can miss. C_LIO_LIThe method uncovers a size-dependent division of labor: on compact RNAs that can be scored exhaustively, atom-level statistical potentials such as rsRNASP remain strongest, whereas on >200 nt RNAs--where the strongest local comparator times out on most targets under the single-threaded runtime budget used here--SpecRNA-QA provides the strongest signal we observed. C_LIO_LIHeat-kernel traces at intermediate diffusion times emerge as the most discriminative spectral features and form an interpretable bridge between local packing and long-range tertiary organization. C_LIO_LIA training-free heuristic variant of SpecRNA-QA retains informative spectral signal without any labeled QA data, supporting the interpretation of the learned model as amplifying a real structural signal rather than overfitting one. C_LI

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Zhu, Y., Zhang, H., Calhoun, V. D., Bi, Y.. 2026-04-09. Spectral Graph Features for Reference-free RNA 3D Quality Assessment. https://doi.org/10.64898/2026.04.06.716854

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Heterogeneous Graph Contrastive Learning for Drug-Gene-Disease Motif Prediction

Drug repurposing and target discovery offer critical strategies for advancing therapeutic development by uncovering the potential biological pathways and novel associations among drugs, genes, and diseases. However, experimental discovery remains expensive and time-consuming, which limits the scalability of large-scale studies. In addition, existing computational approaches often struggle to effectively integrate heterogeneous biomedical data, capture the complex higher-order topological signatures of biological interactomes, and generalize to unseen entities. Here, we present HANAMI (Heterogeneous grAph coNtrastive leArning for drug-gene-disease Motif predIction), a multi-view deep graph learning framework designed to model complex interactions among drugs, genes, and diseases. HANAMI integrates diverse heterogeneous biomedical knowledge, including chemical structures, genomic sequences, and clinical phenotypes, and leverages relation-aware topology encoding, structure-aware aggregation, and contrastive learning to enable accurate motif prediction with biological context from the network. Systematic evaluation on benchmark datasets shows that HANAMI achieves up to 6% improvements over existing state-of-the-art methods in predicting drug-gene-disease motifs. The framework further demonstrates strong inductive generalization, maintaining an [~]18% performance advantage in zero-shot settings involving previously unseen entities. Beyond predictive performance, HANAMI effectively prioritizes drug-disease relationships investigated in Phase II or III trials while identifying candidate genes that suggest plausible mechanistic links. Together, HANAMI provides a computational framework for interpreting complex biomedical interactions, offering a scalable foundation to accelerate drug repurposing and therapeutic innovation.

bioinformatics↗

PTMExplorer: A Multi-Dimensional Integrative Visualization Platform for Protein Post-Translational Modification Function and Structure

Deciphering the functions of post-translational modifications (PTMs) is a critical bridge connecting large-scale modification proteomics data to mechanistic studies. However, most existing tools for visualizing PTM omics data are limited to site catalogs or single-dimensional feature displays. They lack the capability to simultaneously map user-derived differential modification sites onto multi-dimensional contexts, including protein three-dimensional (3D) structure, evolutionary conservation, functional sites, and disease associations. This limitation makes it difficult for researchers to rapidly assess the biological importance of candidate sites from among a vast number of differentially modified sites. Here, we present PTMExplorer, an interactive platform for the multi-dimensional visualization of protein PTMs. PTMExplorer comprises three core modules: PTM Inspector, built upon ProtVista, provides a multi-track, sequence-feature integrated view incorporating intrinsically disordered region (IDR) prediction (via flDPnn), surface accessibility calculation (via FreeSASA), and UniProt functional annotations; PTM 3D Locator, leveraging the Nightingale/Mol* engine, anchors modification sites onto AlphaFold/Protein Data Bank (PDB) 3D structures through residue mapping via PDBe-SIFTS; and PTM Overview, utilizing the R circlize package, presents a panoramic polar circos plot illustrating modification distribution and inter-group differential regulation. Additionally, three major disease-associated modification databases (PTMD, qPTM, and PhosCancer) are integrated as PTM-Disease Nexus, enabling co-localization comparison between user-defined differential sites and reported disease-related sites. PTMExplorer currently supports eight model organisms, accepts user-uploaded differential analysis results, and provides multi-dimensional annotations and various visualization options (https://www.bioladder.cn/PTMExplorer/). Using a multi-omics dataset from hepatocellular carcinoma (18 patients, 9 modification types) as a case study, we demonstrate the practical utility of PTMExplorer in screening potential biomarkers, revealing multi-modification coordination mechanisms, and distinguishing between absolute and relative quantification patterns.

bioinformatics↗

Integrative analysis of the MDM2 promoter switch and cellular lineage plasticity in colorectal cancer: a contrast between the autonomous-proliferation type (CIN/CMS2) and the environment-adaptive type (MSI/gastric metaplasia)

Background: Biomarkers that stratify colorectal cancer (CRC) by therapeutic responsiveness and are measurable directly in biopsy specimens remain insufficiently established. We investigated whether usage of the dual MDM2 promoters (P1/P2) acts as a molecular switch separating two diametrically opposed CRC phenotypes: a chromosomal instability type and an environment adaptive type (microsatellite instability/serrated pathway with gastric metaplasia). Methods: Sixty three organoid samples from 22 patients with CRC were classified morphologically by deep learning (VGG16) and molecularly by an MDM2 Splicing Index derived from expression arrays. The P1 and P2 signatures (gene sets characterizing P1 and P2dominant samples) were externally validated in TCGA-COAD/READ (n = 624) and GSE39582 (n = 536), 1,160 cases in total, and therapeutic implications were tested in public cell line panels (GDSC2, DepMap) and in 65 lines of an independent patient derived CRC organoid biobank. Results: Deep learning morphological classification reached 98.5% test accuracy (64/65), and morphology corresponded to P1/P2 isoform usage: Type1 (compact glandular) morphology predominated in P1 dominant samples (median Type1 fraction 0.826 versus 0.444) and non Type1 (cystic mucinous) morphology in P2 dominant samples (AUC 0.79). Both signatures differed across the four consensus molecular subtypes , and the P2 signature was higher in mismatch repair deficient (microsatellite-unstable) tumors. Promoter usage quantified directly (P2_index) was higher in TP53 wild type tumors , consistent with P2 being p53-inducible. TP53 wild type cell lines were more sensitive to the MDM2 inhibitor Nutlin 3a and were more dependent on MDM2 in the DepMap CRISPR screen ; among 198 GDSC2 drugs, Nutlin 3a correlated most strongly with the P2 score. In the independent biobank, TP53 wild type lines (17) were more sensitive to nutlin-3 than mutant lines (48) (median log(IC50) 1.386 versus 4.283). Conclusions: MDM2 promoter choice (P1/P2) co-varies with the lineage identity of cancer cells and with the secretory, mucin rich character of the tumor tissue, consistent with a molecular-switch role alongside p53 suppression. The MDM2 P1/P2 ratio, measurable by RT qPCR or targeted NGS, is a candidate molecular-classification and therapeutic-stratification biomarker corresponding robustly to CMS, MSI, and TP53 mutation status.

bioinformatics↗